SLC5A2 and kidney disorder: This meta-analysis has a number of strengths: it addresses the scarcity of a single standardised kidney disease progression outcome in previous meta-analyses, and takes into account all of the available large-scale randomised evidence (at the time of publication) from around 90 000 people recruited into 13 relevant SGLT2 inhibitor clinical trials.